Science Week — #18

If your week included a one‑in‑ten‑billion particle doing something it almost never does, a new opening to apply to be an astronaut, and a tiny enzyme hiding in plain sight in our immune system… that’s a good science week. This is episode 18 of Science Week, looking at the science of the week for November 10.

And it’s a nicely varied mix. From deep space to deep tissue, we’ve got new methods, new warnings, and a few big swings at the Moon. No capes, no hype—just what actually happened.

Let’s start with life and the brain, because a single engineered protein just nudged memory in mice—and that’s the sort of sentence that makes you sit up.

A team led by Mi Hee Lim at KAIST reported an engineered zinc‑finger‑derived protein that cut down amyloid‑beta deposits, reduced microglial activation—the brain’s immune sentinels—and improved recognition memory in transgenic mice. That’s the classic Alzheimer’s triangle: plaques, inflammation, behavior.

Important to park the excitement where it belongs. This is a mouse study. The material we have doesn’t give a sample size, and mice engineered to develop amyloid pathology are a model, not the disease itself. It’s promising that a single protein construct hit multiple targets—plaques and immune activation—and that behavioral readouts improved. But preclinical steps don’t translate on their own.

Right, but it’s interesting that it’s a protein derived from zinc‑fingers—those are modular DNA‑binding designs researchers use like Lego for biology. The idea you could dial in a targeted effect and see both less plaque and better memory behavior—if that even partly holds in higher models—could expand the toolkit.

Next steps would be replication, dose‑response, safety, and ultimately human studies. None of that is in hand yet. For now: a clever molecular approach with encouraging mouse‑level outcomes.

Also on the body’s hardware: a fresh way to look inside spinal discs while they’re under load. Researchers led by Brian Bay and Catherine Disney introduced TomoSAXS, a full‑field 3D X‑ray scattering tomography that visualizes how collagen fibrils and fibers interact in intact intervertebral discs. Published in Nature, which tells you the methods angle here matters.

It’s a technique paper, not a therapy. The value is that it observes fiber and fibril orientations in 3D while the tissue is bearing load. Intervertebral discs are composite structures; how the collagen network responds to stress is central to degeneration and back pain. Traditional imaging shows anatomy; scattering tomography shows micro‑architecture.

And crucially, intact discs—so you can see how the parts talk to each other in situ, not just in slices on a bench. That bridges biomechanics and biology.

Caveats are straightforward: this is about measurement, not patient outcomes. The material doesn’t list population sizes because we’re talking specimens and fields of view, not clinical cohorts. If the method spreads, it could guide models of disc failure and, downstream, inform interventions. But that path is long.

Staying in the realm of fundamental biology, researchers at Memorial Sloan Kettering identified DHRS7 as the enzyme responsible for the 5‑oxoETE pathway, and they showed that this pathway does two jobs during intestinal inflammation: it recruits immune cells and shields healthy tissue.

That’s a neat mechanistic clarification. When a pathway both rallies the troops and protects the neighborhood, you have a balancing act that medicine often tries to tweak. Knowing the enzyme—DHRS7—gives you a handle.

It’s like finding out who’s quietly running logistics and also putting up sandbags. If you can tune that person’s schedule, you might get better outcomes.

The usual caution: the item doesn’t specify models, sample sizes, or whether this is human tissue, animal, or a mix. Science Daily is cited for potential applications, but that’s forward‑looking. At this stage, it’s target identification with dual‑role evidence in intestinal inflammation. Useful for drug discovery conversations; not a therapy yet.

Let’s step from micro to macro: orbit. Scientists from the European Space Agency and researchers at North Carolina State University, Duke, and the UK’s space agency warned that small debris in Earth orbit is rising fast, increasing collision risk. They specifically pointed to ongoing reentries from megaconstellations like Starlink as part of the picture.

This is a risk assessment and a warning, not a new debris census in our notes here. The core claim is trend direction: more small fragments, more potential for collisions, and a cloud of debris that threatens satellite operations. There aren’t hard counts or cross‑sections in what we have.

Still, the storyline is clear: our orbital neighborhood is getting busier, and fragments multiply risk. When little things hit, they make more little things. It’s the world’s least fun chain reaction.

The practical takeaway is vigilance. Tracking, design choices that limit fragmentation, and responsible end‑of‑life handling all reduce risk—but to be precise, none of those specifics are enumerated in the item. What is stated is the warning itself and the set of institutions sounding it.

Now, Moon. NASA announced contracts worth up to ten billion dollars for lunar cargo delivery, a nuclear‑powered rover, and related launch services. The aim is to move the plan for a Moon base by 2032 along. That’s the kind of number that says, “We’re building infrastructure.”

“Up to ten billion” is an important phrase—it likely covers multiple task orders over time, not a single check today. The material frames this as advancing the 2032 base plan. It also notes that earlier NASA opened the Commercial Lunar Payload Services competition, with SpaceX, Blue Origin, and six additional firms invited. We’re seeing the scaffolding: delivery services, surface assets, and launches stitched together.

And a nuclear‑powered rover on the list hints at longer‑duration exploration. Sunlight’s great until it isn’t; power that runs through the night changes what you can do.

As always, timelines in space are ambitions, not guarantees. The item doesn’t give milestones or awardees beyond the categories. The prudent reading is: sustained investment in lunar logistics is continuing, with commercial partners in the mix.

If you’ve ever dreamed of riding along, NASA also opened applications for a new astronaut class. They announced it at the Kennedy Space Center on November 9, and the deadline is December 3. U.S. citizens only, and the pitch is tied to Artemis missions—lunar base construction and, down the road, Mars.

It’s a recruitment drive, not a seat assignment. The pipeline is long: applications, selection, training, mission assignments years later. The first report was on November 7, and the agency’s making the case that the corps needs people for lunar operations.

Still, it’s a very concrete door opening. And a deadline that says: get your references now. “Reason for leaving your last job?” “The Moon called.”

To keep it grounded, applying is one thing, being selected is another, and the material doesn’t say how many slots or what the class size will be.

A quick follow‑up on a story we covered last week: the Neil Gehrels Swift Observatory. We talked about its end of scientific operations and the failed rescue attempt. Since then, NASA said the 22‑year‑old Swift Observatory burned up in Earth’s atmosphere over Indonesia on November 4, ending a two‑decade mission—and causing no injuries.

That closes the loop. It was a prolific observer of gamma‑ray bursts and supernovae for nearly two decades, and now reentry is complete. The new piece here is the confirmed breakup location and that there were no injuries.

Farewell to a workhorse. Space keeps moving.

Meanwhile, China unveiled a three‑year plan for a crewed Moon landing. Wang Xiang, the chief designer, laid it out at the 7th Manned Space Symposium in Beijing. The plan is a sequence: uncrewed test flights, orbital docking rehearsals, and then a three‑day surface mission. First missions are slated for early 2027, and a crewed landing sits within that roadmap.

That’s a roadmap announcement, not a completed schedule. The specifics we have are the structure—tests, docking practice, a defined surface duration—and the early 2027 start for initial missions. It signals intent and sequencing. As always, execution will depend on hardware readiness and test outcomes, which aren’t detailed here.

But it does reinforce the point: multiple players are now building serious lunar plans, with timelines you can put on a coffee mug.

Down at the smallest scales, CERN’s LHCb experiment reported evidence of a B‑zero meson decaying into a pair of muons—a process expected about once in ten billion decays. That’s “rare” in the same way a blue moon is common. It’s a precision check of the Standard Model’s bookkeeping.

“Evidence” matters as a term. The item doesn’t give a statistical significance level or whether this is an observation at a particular confidence threshold. It also notes, via Education Times, that recent UK funding withdrawals could jeopardize continued British involvement. Science Daily is mentioned but the detail trailing after that is cut off in what we have, so we won’t fill in blanks.

The scientific point is that when a decay is that rare, just seeing it at the expected rate is a stress test. If it deviated, it could hint at new physics; if it matches, it tightens the screws on the theory.

Either way, you need data and continuity. Rare processes require huge samples and patient analysis. If parts of the collaboration lose support, that continuity is harder to maintain. That’s the broader context flagged here.

So what did we learn this week about how the world works? That method matters—being able to see collagen fibrils shift under load, or to name the enzyme quietly running a double duty in inflammation, opens practical doors later. That ambition matters—ten billion dollars “up to,” astronaut applications, a three‑year lunar playbook—these are serious bets on a sustained presence beyond Earth.

And that maintenance matters. Debris warnings remind us that growth without guardrails is costly. Long‑run experiments at CERN hinge on stable support to catch a one‑in‑ten‑billion whisper. Mouse memory improvements and clean tissue mechanics are steps toward outcomes, not endpoints.

The thread is patience paired with momentum. You build the tools, you hire the people, you tidy the orbit, and you check your math—all so that big leaps don’t outrun the ground under them.

And you write deadlines in pen. December 3 is not a flexible suggestion.

If you want to keep a clear view as all this unfolds, head to factslane.com or find the FactsLane app on the App Store and Google Play. Pick the topics, people, companies, and places you care about, and FactsLane keeps track and catches you up with checked facts.

And if you like your weeks well‑scanned, try our sister shows too—Good Week and Tech Week. They’re solid companions for the curious.

That’s it for this run. Thanks for listening, stay curious, and we’ll see you next week.

Take care, and see you next week.